## Fluoroquinolone Selection for Atypical CAP **Key Point:** Moxifloxacin is the preferred fluoroquinolone for community-acquired pneumonia caused by atypical organisms (Mycoplasma, Chlamydia, Legionella) due to its superior intracellular penetration and broad spectrum. ### Why Moxifloxacin Excels in Atypical CAP Moxifloxacin is a respiratory fluoroquinolone specifically designed for respiratory tract infections. It achieves: - Excellent lung tissue and intracellular concentrations - Potent activity against Mycoplasma pneumoniae and Chlamydia pneumoniae - Superior gram-positive coverage (Streptococcus pneumoniae) - Anaerobic coverage (atypical for fluoroquinolones) ### Fluoroquinolone Activity Against Atypical Organisms | Fluoroquinolone | Mycoplasma | Chlamydia | Legionella | Lung Penetration | Gram-Positive | |---|---|---|---|---|---| | **Moxifloxacin** | **Excellent** | **Excellent** | **Excellent** | **Excellent** | **Good** | | Ciprofloxacin | Poor | Moderate | Good | Good | Poor | | Gemifloxacin | Good | Good | Good | Good | Excellent | | Ofloxacin | Moderate | Moderate | Moderate | Moderate | Poor | **High-Yield:** Moxifloxacin is the **respiratory fluoroquinolone** of choice for CAP with atypical pathogens. It is monotherapy-sufficient and does not require combination with a macrolide. ### Clinical Application Moxifloxacin 400 mg once daily (oral or IV) for 5–7 days is guideline-recommended for atypical CAP. It covers the entire spectrum of CAP pathogens (atypical, gram-positive, gram-negative) in a single agent, improving compliance and reducing drug interactions. **Clinical Pearl:** Gemifloxacin, though also effective against atypical organisms, is less commonly used in India and has a higher incidence of rash. Moxifloxacin remains the standard respiratory fluoroquinolone in most guidelines. [cite:Harrison 21e Ch 297]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.